Sign in
Taking people in United StatesPhase 2

Naxitamab Added to Chemotherapy for Newly Diagnosed High-Risk Neuroblastoma

Tests naxitamab with standard chemotherapy in children with newly diagnosed high-risk neuroblastoma.

Key facts

Who runs it
Giselle Sholler
Where
Augusta, Austin, Birmingham, Charleston, Charlotte, Durham, Gainesville, Hartford, Hershey, Honolulu, Little Rock, Louisville, Miami, Minneapolis, Oakland, Orlando, Portland, Richmond, San Diego, St Louis, and Winston-Salem, United StatesSee the 21 sitesAlso in 3 other countries, 5 sites
Registry title
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Status
Recruiting
Phase
Phase 2
People taking part
93 people, planned
Started
14 Sept 2022
Expected to end
Sept 2036
Type of study
Interventional
Treatments tested
  • Naxitamab
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with newly diagnosed high-risk neuroblastoma who have not yet had real cancer treatment. Naxitamab is added to the first 5 cycles of chemotherapy.

Age
Older than 12 months at enrollment and 21 years or younger at first diagnosis.
Sex
All sexes can join.
Disease stage
Newly diagnosed neuroblastoma or ganglioneuroblastoma (nodular or intermixed), shown by tissue exam or tumor cells in bone marrow with raised urine catecholamine metabolites. Stage M disease, or stage MS, L2 or incompletely resected L1 disease with high-risk features such as MYCN amplification or unfavorable histology, depending on age.
Earlier treatment
No earlier systemic treatment, except emergency radiation to life- or function-threatening sites and/or no more than 1 cycle of chemotherapy.
Biomarker or test result
MYCN amplification (more than 4-fold increase in MYCN signals), or unfavorable biology such as unfavorable histology, diploid tumor or segmental chromosome changes, depending on age and stage.

Main reasons for not taking part

  • Younger than 1 year
  • Aged 12-18 months with stage M disease, or stage L2 disease with favorable biology
  • Immunosuppressive treatment within 4 weeks before enrollment
  • Poor lung function, such as breathlessness at rest or oxygen below 94%
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Diagnosis: Subjects must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular or intermixed) verified by histology or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites. Subjects with the following disease stages at diagnosis are eligible, if they meet the other specified criteria:
  • Subjects with newly diagnosed neuroblastoma with INRGSS Stage M disease with either of the following features:; MYCN amplification (> 4-fold increase in MYCN signals as compared to reference signals), regardless of additional biologic features; OR; 365 days to ≥ 547 days of age without MYCN amplification, but unfavorable biologic features such as unfavorable histology (INPC) or diploid tumor (DNA index=1) or the presence of any segmental chromosome aberration (SCA) (somatic copy number loss at 1p, 3p, 4p, or 11q or somatic copy number gain at 1q, 2p, or 17q); OR; Age > 547 days of age regardless of biologic features; Subjects with newly diagnosed neuroblastoma with INRGSS Stage MS disease with either of the following:; MYCN amplification (> 4-fold increase in MYCN signals as compared to reference signals); OR; 365 days to ≥ 547 days (18 months) of age without MYCN amplification, but unfavorable biologic features such as unfavorable histology (INPC) or diploid tumor (DNA index=1) or SCA as above; Subjects with newly diagnosed neuroblastoma INRGSS Stage L2 disease with either of the following:; MYCN amplification (> 4-fold increase in MYCN signals as compared to reference signals); OR; 18 months to <5 years of age without MYCN amplification, but with unfavorable histology (INPC); OR; ≥5 years of age without MYCN amplification, but with undifferentiated or poorly differentiated INPC Subjects with newly diagnosed neuroblastoma INRGSS Stage L1 disease that is incompletely resected with MYCN amplification; Subjects > 547 days of age initially diagnosed with INRGSS Stage L1, L2 or MS disease who progressed to Stage M without prior chemotherapy may enroll within 4 weeks of progression to Stage M; Subjects ≥ 365 days of age initially diagnosed with MYCN amplified INRGSS Stage L1 disease who progress to Stage M without systemic therapy may enroll within 4 weeks of progression to Stage M
  • Subjects must be age ≤ 21 years at initial diagnosis
  • Subjects must be >12 months of age at enrollment
  • Adequate cardiac function defined as:; Shortening fraction of ≥ 27% by echocardiogram, or; Ejection fraction of ≥ 50% by radionuclide evaluation or echocardiogram
  • Adequate liver function must be demonstrated, defined as:; Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND; ALT (SGPT) < 5 x upper limit of normal (ULN) for age
  • 1. Subjects must have adequate renal function defined as:; For subjects < 17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Bedside Schwartz equation (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Bedside Schwartz equation is: [(0.413) X (Height in cm)] / SCr; For subjects ≥17 years old: estimated Glomerular Filtration rate (eGFR) as calculated from the Cockcroft and Gault formula (in units of mL/min/1.73 m2) or via radioisotope GFR of ≥ 70 mL/min/1.73 m2. The Cockcroft and Gault formula is: [(140-age) x (Wt in kg) x (0.85 if female)] / (72 x SCr); OR a 24 hour urine Creatinine clearance ≥ 70 mL/min/1.73 m2
  • A negative serum pregnancy test is required for subjects of childbearing potential (≥13 years of age or after onset of menses)
  • Both male and female post-pubertal study subjects must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of <1% per year when used consistently and correctly) from the time of informed consent (and assent, as applicable) until 6 months after study treatment discontinuation. Such methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, sexual abstinence
  • Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines and applicable local regulations

Who cannot take part

  • Subjects who have had prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than 1 cycle of chemotherapy
  • Treatment with immunosuppressive treatment (topical, inhaled and short-term emergency steroids excluded) within 4 weeks prior to enrollment
  • Subjects receiving any investigational drug concurrently
  • Subjects with any other medical condition, including but not limited to malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a subject's ability to sign or the legal guardian's ability to sign the informed consent, and subject's ability to cooperate and participate in the study
  • Subjects with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of investigational medicinal products (IMPs) or to significantly increase the severity of the toxicities experienced from trial treatment
  • Subjects who are less than 1 year of age
  • Subjects who are 12-18 months of age with INRGSS Stage M and all stage L2 subjects with favorable biologic features (i.e., nonamplified MYCN, favorable pathology, and DNA index > 1) are not eligible
  • Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. In addition, room air pulse oximetry < 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated
  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study.)

Where in United States

Also in 3 other countries, 5 sites

  • Augusta University HealthAugusta, United StatesContact: Kimberly GrayTaking people
  • Dell Children's Blood and Cancer CenterAustin, United StatesContact: Rhea RobinsonTaking people
  • University of Alabama/Children's of AlabamaBirmingham, United StatesContact: Bridget TateTaking people
  • Medical University of South CarolinaCharleston, United StatesContact: Shanta SalzarTaking people
  • Levine Children's HospitalCharlotte, United StatesContact: Jontyce GreenTaking people
  • Duke UniversityDurham, United StatesContact: Morgan LowTaking people
  • University of FloridaGainesville, United StatesContact: Ashley BayneTaking people
  • Connecticut Children's HospitalHartford, United StatesContact: Adam BarselauTaking people
  • Penn State Milton S. Hershey Medical Center and Children's HospitalHershey, United StatesContact: Penn State Clinical TrialsTaking people
  • Kapiolani Medical Center for Women and ChildrenHonolulu, United StatesContact: Andrea SiuTaking people
  • Arkansas Children's HospitalLittle Rock, United StatesContact: Susan HallTaking people
  • Norton Children's Research Institute/Affiliated with University of Louisville School of MedicineLouisville, United StatesContact: Jennifer MillerTaking people
  • Nicklaus Children's HospitalMiami, United StatesContact: Aixa GuadarramaTaking people
  • Children's Hospital and Clinics of MinnesotaMinneapolis, United StatesContact: Pauline MitbyTaking people
  • UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Jennifer Michlitsch (principal investigator)Taking people
  • Arnold Palmer Hospital for ChildrenOrlando, United StatesContact: Marie FrankosTaking people
  • Randall Children's HospitalPortland, United StatesContact: Aaron WhiteTaking people
  • Virginia Commonwealth UniversityRichmond, United StatesContact: Mary MaduTaking people
  • Rady Children's HospitalSan Diego, United StatesContact: Megan SaenzTaking people
  • Cardinal Glennon Children's HospitalSt Louis, United StatesContact: Gina MartinTaking people
  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: BCC EnrollNo longer taking part

About the trial

What the trial wants to find out

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.

The group in the trial

  • HRNB Newly diagnosed subjectsTreatment being tested

    5 cycles of standard of care induction + naxitimab Naxitimab on Days 1, 3, and 5 of each cycle

    Treatment: Naxitamab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Plain-language title
Naxitamab Added to Chemotherapy for Newly Diagnosed High-Risk NeuroblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 August 2026